Lorena Raquel Lerner - 06 Aug 2025 Form 3 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Science Officer
Signature
/s/ Esther Cho, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
06 Aug 2025
Net transactions value
$0
Form type
3
Filing time
15 Aug 2025, 16:34:50 UTC
Next filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lerner Lorena Raquel Chief Science Officer C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON /s/ Esther Cho, Attorney-in-Fact 15 Aug 2025 0002081359

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KROS Common Stock 35,000 06 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KROS Employee Stock Option (Right to Buy) 06 Aug 2025 Common Stock 10,879 $43.99 Direct F2
holding KROS Employee Stock Option (Right to Buy) 06 Aug 2025 Common Stock 7,500 $54.38 Direct F3
holding KROS Employee Stock Option (Right to Buy) 06 Aug 2025 Common Stock 23,000 $56.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person continuing to provide service through each such date.
F2 One-fourth (1/4th) of the shares subject to the option vested on May 9, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F3 One-fourth (1/4th) of the shares subject to the option vested on February 16, 2024, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F4 One-fourth (1/4th) of the shares subject to the option vested on February 13, 2025, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.